LAB Director Granted 94,592 RSUs & 125,660 Options in Routine Filing
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Standard BioTools (NASDAQ:LAB) submitted a routine Form 4 disclosing director Troy Cox received 94,592 restricted stock units (RSUs) that vest in full by June 20 2026 and a stock option for 125,660 shares at an exercise price of $1.05, vesting in 12 equal monthly installments beginning July 20 2025.
Following these grants, Cox’s beneficial ownership stands at 256,412 common shares. No shares were sold, and the filing contains no additional transactions or financial disclosures.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to buy) | 125,660 | $0.00 | $0.00 |
| Grant/Award | Common Stock | 94,592 | $0.00 | $0.00 |
Footnotes (2)
- F1. Represents Restricted Stock Units ("RSUs") that vest in full on the earlier to occur of June 20, 2026 and one day prior to the date of the Company's next annual meeting of stockholders, subject to the Reporting Person's continued service through the applicable vesting date. Each RSU represents the right to receive one share of common stock upon vesting.
- F2. The Option becomes exercisable in twelve equal monthly installments beginning on July 20, 2025, subject to the Reporting Person's continued service through the applicable vesting date.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How many RSUs did LAB grant to director Troy Cox on 06/20/2025?
What are the key terms of the new LAB stock option granted to Troy Cox?
AI-generated analysis. How Rhea-AI works. Not financial advice.